Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer
SQUARE
1 other identifier
observational
300
1 country
1
Brief Summary
This study aims to assess overall survival, quality of life and resection rates in locally advanced pancreatic cancer
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 28, 2022
CompletedStudy Start
First participant enrolled
April 19, 2022
CompletedFirst Posted
Study publicly available on registry
May 2, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2028
ExpectedNovember 30, 2022
November 1, 2022
3 years
March 28, 2022
November 23, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
Median Overall Survival
Median overall survival for patients with locally advanced pancreatic cancer stratified for treatment allocation
From date of inclusion until the date of death from any cause, assessed up to 72 months
Resection
Rates of resection among patients with locally advanced pancreatic cancer stratified for treatment allocation
From the time of inclusion to end of study follow up or date of death from any cause, whichever came first, up to 72 months
Secondary Outcomes (9)
Oncological treatment compliance
From the time of inclusion to end of study follow up or date of death from any cause, whichever came first, up to 72 months
Chemotherapy response
From the time of inclusion to end of study follow up or date of death from any cause, whichever came first, up to 72 months
Predictors of resectability
From the time of inclusion to end of study follow up or date of death from any cause, whichever came first, up to 72 months
Quality of Life at baseline
At first visit/inclusion
Quality of Life at 3 months after inclusion
Quality of Life at 3 months after inclusion
- +4 more secondary outcomes
Eligibility Criteria
Patients with a confirmed or suspected non-endocrine invasive pancreatic primary tumor that is classified as borderline resectable or locally advanced disease
You may qualify if:
- Confirmed or suspected invasive pancreatic primary tumor
- Tumor classified as borderline resectable or locally advanced disease according to NCCN guidelines
You may not qualify if:
- Suspected endocrine tumor
- Suspected non-pancreatic periampullary tumor
- Distant metastasis
- Age \< 18 years
- Patient unable to understand verbal or written information interfering with informed consent or treatment
- Mental or organic disorder interfering with informed consent or treatments
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Umeå Universitylead
- University Hospital, Linkoepingcollaborator
- Lund University Hospitalcollaborator
- Sahlgrenska University Hospitalcollaborator
- Karolinska University Hospitalcollaborator
- University Hospital, Umeåcollaborator
Study Sites (1)
Surgical Clinic at Umeå University Hospital
Umeå, 90185, Sweden
Biospecimen
Plasma biobanking. Tissue Microarray Construction from formalin fixed paraffin embedded tissue
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 28, 2022
First Posted
May 2, 2022
Study Start
April 19, 2022
Primary Completion
May 1, 2025
Study Completion (Estimated)
May 1, 2028
Last Updated
November 30, 2022
Record last verified: 2022-11